New molecular targets for treatment of lymphoma

Current Oncology Reports

Volumn 6, Issue 5, 2004, Pages 360-368

  Pro, Barbara ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CD20 ANTIBODY; CD30 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; KP 3721; KP 86328; MONOCLONAL ANTIBODY; OBLIMERSEN; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TEMSIROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VINCRISTINE;

BLOOD TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; FEVER; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; THROMBOCYTOPENIA;

EID: 4544345579     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0062-x     Document Type: Review

References (63)

1. Muratani M, Tansey WP: How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003, 4:192-201.
2. Adams J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003, 8:307-315.
3. O'Connor OA, Wright J, Moskowitz CH, et al.: Promising activity of the proteasome inhibitor bortezomib (Velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma [abstract]. Blood 2003, 102:2346.
4. Goy A, Hart S, Pro B, et al.: Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory indolent or aggressive lymphoma [abstract]. Blood 2003, 102:627.
5. Assouline S, Belch A, Sehn L, et al.: A phase II study of bortezomib in patients with mantle cell lymphoma [abstract]. Blood 2003, 102:3358.
6. Zheng B, Georgakis GV, Li Y, et al.: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004, 10:3207-3215.
7. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
8. Plate K: From angiogenesis to lymphangiogenesis. Nat Med 2001, 7:151-152.
9. Olofsson B, Korpelianen E, Pepper MS, et al.: Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998, 95:11709-11714.
10. Ribatti D, Vacca A, Bertossi M, et al.: Angiogenesis induced by B-cell non-Hodgkin's lymphomas: lack of correlation with tumor malignancy and immunologic phenotype. Anticancer Res 1990, 10:401-406.
11. Ribatti D, Vacca A, Marzullo A, et al.: Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer 2000, 85:171-175.
12. Vacca A, Ribatti D, Roncali L, Dammacco F: Angiogenesis in B cell lymphoproliferative diseases: biological and clinical studies. Leuk Lymphoma 1995, 20:27-38.
13. Salven P, Orpana A, Teerenhovi L, Joensuu H: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000, 96:3712-3718.
14. Pro B, Younes A, Albitar M, et al.: Thalidomide for patients with recurrent lymphoma. Cancer 2004, 100:1186-1189.
15. Drach J, Kaufmann H, Puespoek A, et al.: Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma [abstract]. Blood 2002, 100:606.
16. Fresno Vara JA, Casado E, et al.: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204.
17. Lu Y, Wang H, Mills GB: Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003, 7:205-228.
18. Abbott RT, Tripp S, Perkins SL, et al.: Analysis of the PI-3-kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod Pathol 2003, 16:607-612.
19. Xu G, Zhang W, Bertram P, et al.: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004, 24:893-900.
20. Huang S, Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003, 3:371-377.
21. Sawyers CL: Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003, 4:343-348.
22. Panwalkar A, Verstovsek S, Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004, 100:657-666.
23. Witzig TE, Geyer SM, Salim M, et al.: A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell lymphoma: interim analysis of 18 patients [abstract]. Blood 2003, 102:2374.
24. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
25. Younes A, Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003, 21:3526-3534.
26. Bhardwaj A, Aggarwal BB: Receptor-mediated choreography of life and death. J Clin Immunol 2003, 23:317-332.
27. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
28. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430.
29. Younes A, Aggarwall BB: Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003, 98:458-467.
30. Younes A, Carbone A: CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999, 14:135-143.
31. Wahl AF, Cerveny CH, Klussman K, et al.: SGN-30, a chimeric antibody to CD30, for the treatment of Hodgkin's disease [abstract]. Proc Am Assoc Cancer Res 2002, 43:4979a.
32. Bartlett NL, Bernstein SH, Leonard JP, et al.: Antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies [abstract]. Blood 2003, 102:2390.
33. Ansell SM, Byrd JC, Horwitz SB, et al.: Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL) [abstract]. Blood 2003, 102:632.
34. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
35. Carbone A, Gloghini A: Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas. Am J Clin Pathol 1996, 105:522-523.
36. Carbone A, Gloghini A, Gruss HJ, Pinto A: CD40 antigen expression on Reed-Sternberg cells: a reliable diagnostic tool for Hodgkin's disease [letter; comment]. Am J Pathol 1995, 146:780-781.
37. Kato K, Santana-Sahagan E, Rassenti LZ, et al.: The soluble CD40 ligand, sCD154 in systemic lupus erythematosus. J Clin Invest 1999, 104:947-935.
38. Viallard JF, Solanilla A, Gauthier B, et al.: Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002, 99:2612-2614.
39. Younes A, Snell V, Consoli U, et al.: Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998, 100:135-141.
40. Fiumara P, Younes A: CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 2001, 113:265-274.
41. Younes A: The dynamics of life and death of malignant lymphocytes. Curr Opin Oncol 1999, 11:364-369.
42. Carbone A, Gloghini A, Gattei V, et al.: Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995, 85:780-789.
43. Gruss HJ, Ulrich D, Braddy S, et al.: Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995, 25:2083-2089.
44. Mackay F, Woodcock SA, Lawton P, et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
45. Khare SD, Sarosi I, Xia XZ, et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000, 97:3370-3375.
46. Klein B, Tarte K, Jourdan M, et al.: Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003, 78:106-113.
47. Kolb JP, Kern C, Quiney C, et al.: Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003, 3:261-286.
48. Novak AJ, Bram RJ, Kay NE, Jelinek DF: Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002, 100:2973-2979.
49. Moreaux J, Legouffe E, Jourdan E, et al.: BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone. Blood 2004, 103:3148-3157.
50. Novak AJ, Darce JR, Arendt BK et al.: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103:689-694.
51. Fiumara P, Snell V, Li Y, et al.: Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001, 98:2784-2790.
52. Emery JG, McDonnell P, Burke MB, et al.: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367.
53. Degli-Esposti M: To die or not to die: the quest of the TRAIL receptors. J Leukoc Biol 1999, 65:535-542.
54. Georgakis GV, Li Y, Humphreys R, et al.: Activity of selective agonostic monoclonal antibodies to TRAIL death receptors R1 and R2 in primary and cultured tumor cells of hematological origin [abstract]. Blood 2003, 102:208.
55. Staudt LM, Wilson WH: Focus on lymphomas. Cancer Cell 2002, 2:363-366.
56. Reed JC, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994, 5(Suppl 1):61-65.
57. Hermine O, Haioun C, Lepage E, et al.: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996, 87:265-272.
58. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
59. Webb A, Cunningham D, Cotter F, et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997, 349:1137-1141.
60. Reed JC: Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 1997, 89:988-990.
61. Waters JS, Webb A, Cunningham D, et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:1812-1823.
62. Leonard JP, Hainsworth J, Bernstein S, et al.: Genasense (Oblimersen Sodium, G3139) is active and well-tolerated both alone and with R-CHOP in mantle cell lymphoma (MCL) [abstract]. Blood 2003, 11:490.
63. Pro P, Smith MR, Younes A, et al.: Genasense (Bcl-2 antisense) plus rituximab is active in patients with relapsed or refractory B-cell non-Hodgkins lymphoma [abstract]. Blood 2003, 11:1491.